2) Present diagnostic criteria and physiopathology of hypertrophic cardiomyopathy with illustrated imaging findings.
Learning objectives
Review the classification of cardiomyopathies.
2) Present diagnostic criteria and physiopathology of hypertrophic cardiomyopathy with illustrated imaging findings.
After briefly introducing the classification of cardiomyopathies, we will focus on hypertrophic cardiomyopathy and the respective interest and values of the different imaging tools with emphasis on MR imaging.
Background Definition
The cardiomyopathies (CM) are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually -but not invariably -exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic. [1] Four CM categories were previously described by the WHO Task A more recent classification was introduced in 2006 by the American Heart Association (AHA) [1] , distinguishing primary from secondary cardiomyopathies: 1) Primary cardiomyopathies: affecting solely or predominantly the heart muscle (represent only a few in number) and subdivided into genetic, non genetic or acquired
•
Genetic: HCM, ARVD, left ventricular noncompaction, conduction system disease, ion channelopathies, mitochondrial myopathies, glycogen storage disease • Mixed (genetic/non genetic): dilated cardiomyopathy, primary restrictive non hypertrophied cardiomyopathy • Acquired: myocarditis (inflammatory cardiomyopathy), stress-provoked cardiomyopathy ('Tako-Tsubo'), peripartum, tachycardia-induced, etc.
2) Secondary cardiomyopathies: involving the myocardium as part of a large number and variety of generalized systemic (multiorgan) disorders
• Secondary involvement varies considerably in frequency and degree among these diseases • Examples of such diseases include: infiltrative (amyloïdosis), storage diseases (hemochromatosis, Fabry disease), toxicity, inflammatory (granulomatous -sarcoïdosis), endocrine (diabetes mellitus, hypo/ hyperthyroidism), autoimmune/collagen diseases (systemic lupus erythematosus, sclerodermia)
Hypertrophic cardiomyopathy
Definition: Diffuse or segmental myocardial hypertrophy (with myocardial thickness being measured in end-diastole) in absence of dilatation of the left ventricle (LV) and of another cardiac or systemic disease capable of producing the same visible magnitude of wall thickening, such as hemodynamic stress causing increased afterload, like aortic stenosis and systemic hypertension. [1] Epidemiology:
• The most frequent cardiomyopathy, the disease phenotypes recognized by echocardiography affecting 0.2% of the general population. 
Pathology
Hallmark findings: myocyte disarray [4] : disorganization and malalignment of the myofibrils clearly more extensive than in secondary myocardial hypertrophy [3] , with interstitial fibrosis and abnormal dysplasia of small intramural coronary arterioles. [4] 
Clinical presentation
In most patients with HCM, hypertrophy is manifested during adolescence. Delayedonset hypertrophy can occur in some patients.
Clinical presentation encompasses a wide spectrum of manifestations and pathways of disease progression are diverse: sudden death, end-stage disease heart failure, atrial fibrillation. [6] Genetic testing cannot accurately predict a patient's future prognosis. [6] Penetrance increases with age, but remains less than 100%. Imaging has an important role for both screening and diagnosis of HCM and for follow-up of disease progression.
Imaging findings OR Procedure details Diagnostic criteria
• LV wall thickness ≥ 15 mm in end-diastole with any imaging modality (Fig. 1) ; not an absolute requirement, as patients with a lesser degree of increased wall thickness may also have HCM. [7] Fig 
Hypertrophic Cardiomyopathy Phenotypes
Several different patterns are described, the most frequents being asymmetric (septal), apical, symmetric (concentric) and midventricular. A 'mass-like' form is also described.
Characteristic end-stage and preclinical findings may also be encountered. • First described in Asian individuals (25% of all patients with HCM in Japan), now being diagnosed more commonly in the Western World (less than 2% of HCM patients).
[4] • Differs from typical HCM: relatively good prognosis, rarely associated with sudden cardiac death, frequently complicated by hypertension. [4] • MRI is the best imaging modality for the evaluation of apical HCM [4] , since the diagnosis is missed by echocardiographic studies in about 10% of cases.
[5] Widely available, low cost, non-invasive imaging method. Extent of maximal LV wall thickness may be underestimated by echocardiography compared with CMR ( Fig. 12 and Fig. 13 ) particularly when hypertrophy involves the anterolateral wall [5] and particularly in the apical subtype of HCM [7] : a study found that 6% of patients suspected of having HCM had increased LV wall thickness (predominantly in the anterolateral wall) identified by CMR but not by echocardiography.
[5] 
Transesophageal echocardiography (TEE)
Semi-invasive procedure reserved for special indications. [7] In the latest recommendations of the ACCF/AHA for HCM, TEE can be useful if TTE is inconclusive for therapeutic decision making.
Recommended for the intraoperative guidance of surgical myectomy [5] , to determine the length and extent of myectomy required, to evaluate the presence and severity of mitral regurgitation independent of obstruction [5] , and to identify the presence of abnormal papillary muscle architecture.
Recommended during alcohol septal ablation procedures; contrast-enhanced studies with intracoronary injection of the candidate coronary septal perforator(s) can determine the perfusion bed it supplies.
[5]
Cardiac Magnetic Resonance Imaging
Provides sharp contrast between blood and myocardium and more accurately characterizes the presence, distribution and extent of LV myocardium hypertrophy than echocardiography. [5] Reproducibly assesses the cardiovascular anatomy and ventricular function with accuracy. [7] 
Indicated in patients with suspected HCM when echocardiography is inconclusive for diagnosis and in patients with known HCM when additional information that may have an impact on management or decision making regarding invasive management, such as magnitude and distribution of hypertrophy or anatomy of the mitral valve apparatus or papillary muscles, is not adequately defined with echocardiography. [5]
May be considered in patients with LV hypertrophy if alternative diagnoses to HCM are considered. [5] Recommended when sudden cardiac death (SCD) risk stratification is inconclusive (with late gadolinium enhancement (LGE)).
MRI Sequences
The following sequences are the most widely used to obtain a complete evaluation in known or suspected cases of cardiomyopathy.
• TSE T1 and T2 including T1 fat sat without and with gadolinium • Velocity-encoded cine (VEC) MRI: to quantify flow velocities, assess valvular regurgitation • Late gadolinium enhancement (LGE) imaging: appropriate choice of inversion-time permits selective nulling of the signal of normal myocardium and increases the contrast difference between normal and abnormal myocardium that represents either scarred myocardium or is related to myocardial disarray or local interstitial expansion. [3] • Patterns of LGE may suggest alternative diagnoses (Anderson-Fabry disease, amyloidosis) [5] Cine MR :
• Hyperdynamic left cardiac chamber : increased left ventricular ejection fraction (LVEF) and low end-systolic volume (ESV) are usually observed (unless severe disease -burnout phase). Bernoulli equation according to which maximal flow velocities across a stenosis reflect the severity of obstruction [8] , is used to estimate subaortic gradient :
peak pressure gradient = 4x (peak velocity) 2 • Peak LVOT gradients can be estimated by using VEC MRI in the LVOT plane ; however, turbulence and partial volume effects limits this technique. Currently, better assessment is provided by echocardiography because of its higher temporal resolution when measuring peak instantaneous velocities (Fig. 17) . [4] • Fibrosis: detected on LGE imaging in 80% of patients with HCM, involves predominantly the hypertrophied myocardium but can also be seen in regions of normal thickness myocardium. [7] On average, 10% of the myocardium demonstrates hyperenhancement in HCM. [4] • Pattern of enhancement does not typically correspond to a coronary vascular distribution. [4] Patchy midwall enhancement often limited to the midwall or subepicardium with multiple foci is the most common pattern in HCM [4] , with a predominant involvement of the junction of the ventricular septum and RV free wall (most prominent site of myocardial scarring and myocardial fiber disarray) (Fig. 18) 
Perfusion defect
Severity of perfusion impairment in HCM patients is correlated with the degree of LV hypertrophy [4] .
• VEC MRI allows measurement of coronary blood flow to the LV myocardium in the coronary sinus, which can then be normalized by the ventricular mass (to express flow as milliliters per minute per gram of LV myocardium).
• Coronary flow reserve (ratio of vasodilator-induced to rest coronary flow) was 1.72 ± 0.49 in HCM compared with 3.01 ± 0.75 in normal patients.
LV dilatation with diminished EF -burned out phase (Cine MR)
• Correlates with heart failure unresponsive to therapy. 
Miscellaneous
• LA remodelling and dilatation predict mortality and heart failure. [6] • The SAM can cause a secondary mitral valve regurgitation [4] , that can be identified with cine MR, as a signal void that projects in LA during systole (Fig. 16) . Volume of mitral valve regurgitation can be quantified by calculating difference in stroke volume of the ventricles or measuring the difference in the inflow and outflow volumes of the LV by means of VEC MRI.
• Apical aneurysms (Fig. 19) 
Cardiac Tomodensitometry
The role of CT scan is limited to patients having contraindication(s) to MRI since it implies radiation and use of intravenous contrast and cannot provide detailed myocardial tissue characterization.
Cardiac CTA in HCM is recommended to assess coronary anatomy for patients with chest discomfort and a low likelihood of CAD due to its high negative predictive value to exclude CAD (coronary angiography being recommended for high to intermediate risk patients). [5] Recent studies have shown computed tomography coronary angiography to be useful in planification of alcohol septal ablation procedure in HCM by identifying the target septal perforator.
Nuclear medicine : myocardial scintigraphy
Useful in detection of large areas of scar tissue in patients with ischemic heart disease. Rarely used in nonischemic cardiomyopathy because of its limited spatial resolution prohibiting detection of small regions of fibrosis. [7] Conclusion Echocardiography is the first-line imaging modality in patients with suspected HCM. MRI is a very useful complementary imaging tool to identify both myocardial tissue and functional abnormalities, and to accurately identify findings that portend major prognostic implications.
Cardiac CT scan has a limited role in HCM (reserved for patients with contraindication(s) to MRI or for evaluation of chest pain in patients with HCM with a low risk of coronary artery disease).
